文献速递产科母胎医学

孕激素联合宫颈环扎降低早产:一项多中心国际回顾性队列研究

Concurrent progestogen and cerclage to reduce preterm birth: a multicenter international retrospective cohort.
PubMed 文献 · Am J Obstet Gynecol MFM · 2024-03-19

这项国际回顾性队列纳入美国与哥伦比亚10家机构2016年6月至2020年6月的699例单胎妊娠,比较宫颈环扎后联合孕激素(561例)与单纯环扎(138例)。联合孕激素与<37周及<34周自发性早产频率更低、分娩潜伏期延长及围产期死亡频率更低相关;亚组分析中阴道孕酮、超声或查体指征环扎者获益证据最强。

要点

  • 宫颈环扎后联合孕激素与<37周自发性早产频率更低相关(31% vs 39%,校正OR 0.59)。
  • 联合孕激素与<34周自发性早产频率更低相关(19% vs 27%,校正OR 0.55)。
  • 联合孕激素与围产期死亡频率更低相关(7% vs 16%,校正OR 0.37)。

核心结论

  • 与单纯宫颈环扎相比,宫颈环扎联合孕激素与自发性早产及早期自发性早产发生率降低相关。
  • 作者指出本研究对亚组分析把握度不足,但超声或查体指征环扎者及使用阴道孕酮者获益证据似乎最强。

研究设计与样本

  • 国际回顾性队列研究,纳入美国与哥伦比亚10家机构2016年6月至2020年6月单胎妊娠、无重大畸形或非整倍体、放置宫颈环扎者。
  • 排除标准为缺乏是否处方孕激素的记录、无法获得分娩结局、以及16周妊娠前自然或人工终止妊娠。
  • 暴露组为环扎后使用孕激素(继续使用或环扎后开始),对照组为环扎后未使用孕激素(整个孕期未用或环扎后停用)。
  • 共699例单胎符合纳入标准:孕激素联合环扎组561例,单纯环扎组138例。
  • 主要结局为<37周自发性早产;次要结局包括<34周自发性早产、分娩时孕周及复合新生儿结局。

主要发现

  • 孕激素组既往自发性早产比例高于单纯环扎组(61% vs 41%;P<.001),其余基线特征相似。
  • 孕激素组中52%使用17-羟孕酮己酸酯每周注射,44%使用阴道孕酮每日,3%使用口服孕酮每日。
  • 孕激素联合环扎组<37周自发性早产频率低于单纯环扎组(31% vs 39%;校正OR 0.59 [0.39-0.89];P=.01)。
  • 孕激素联合环扎组<34周自发性早产频率低于单纯环扎组(19% vs 27%;校正OR 0.55 [0.35-0.87];P=.01)。
  • 孕激素联合环扎组围产期死亡频率低于单纯环扎组(7% vs 16%;校正OR 0.37 [0.20-0.67];P=.001),且至 spontaneous delivery 的潜伏期延长(<37周自发性早产风险比 HR 0.66 [0.49-0.90];P=.009)。

临床怎么用

  • 作者结论认为宫颈环扎联合孕激素与自发性早产及早期自发性早产发生率降低相关。
  • 作者指出本研究对亚组分析把握度不足,但超声或查体指征环扎者及使用阴道孕酮者获益证据似乎最强。

局限性

  • 本研究为回顾性队列研究。
  • 作者指出本研究对亚组分析把握度不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Both progestogens and cerclage are individually effective in preterm birth prevention in high risk pregnancies. However, national and international guidelines cite a lack of data available to comment on the potential benefit of concurrent progestogen therapy after cerclage has been placed. Studies to date have been small with mixed results regarding benefit of concurrent progestogen with cerclage leaving uncertainty regarding best clinical practice. OBJECTIVE: This study aimed to evaluate whether cerclage with progestogen therapy was superior to cerclage alone in the prevention of spontaneous preterm birth in singleton pregnancies. METHODS: This is an international retrospective cohort study of singleton pregnancies, without major anomaly or aneuploidy, and with cerclage placed at 10 different institutions in the United States and Colombia from June 2016 to June 2020. Exclusion criteria were lack of documentation regarding whether progestogen was prescribed, unavailable delivery outcome, and pregnancy termination (spontaneous or induced) before 16 weeks' gestation. The exposure of interest was progestogen use with cerclage placement, which included those who continued to use progestogen or who started progestogen after cerclage. The comparison group consisted of those without progestogen use after cerclage placement, which included those who had no progestogen use during the entire pregnancy or who initiated progestogen and then stopped it after cerclage placement. Progestogen type, cerclage indication, maternal baseline characteristics, and maternal/neonatal outcomes were collected. The primary outcome was spontaneous preterm birth at <37 weeks. The secondary outcomes were spontaneous preterm birth at <34 weeks, gestational age at delivery, and a composite neonatal outcome including ≥1 of the following: perinatal mortality, confirmed sepsis, grade III or IV intraventricular hemorrhage, retinopathy of prematurity, respiratory distress syndrome, and bronchopulmonary dysplasia. There were planned subgroup analyses by cerclage indication, progestogen type (vaginal progesterone vs 17-hydroxyprogesterone caproate), preterm birth history, and site. Continuous variables were compared in adjusted analyses with analysis of covariance, and categorical variables were compared with multivariable logistic regression, adjusting for potential confounders with adjusted odds ratio. A Cox regression survival curve was generated to compare latency to spontaneous delivery, censored after 37 weeks. RESULTS: During the study period, a total of 699 singletons met the inclusion criteria: 561 in the progestogen with cerclage group and 138 with cerclage alone. Baseline characteristics were similar, except the higher likelihood of previous spontaneous preterm birth in the progestogen group (61% vs 41%; P<.001). Within the progestogen group, 52% were on 17-hydroxyprogesterone caproate weekly, 44% on vaginal progesterone daily, and 3% on oral progesterone daily. Progestogen with cerclage was associated with a significantly lower frequency of spontaneous preterm birth <37 weeks (31% vs 39%; adjusted odds ratio, 0.59 [0.39-0.89]; P=.01) and <34 weeks (19% vs 27%; adjusted odds ratio, 0.55 [0.35-0.87]; P=.01), increased latency to spontaneous delivery (hazard ratio for spontaneous preterm birth <37 weeks, 0.66 [0.49-0.90]; P=.009), and lower frequency of perinatal death (7% vs 16%; adjusted odds ratio, 0.37 [0.20-0.67]; P=.001). In planned subgroup analyses, association with reduced odds of preterm birth <37 weeks persisted in those on vaginal progesterone, those without a previous preterm birth, those with ultrasound- or examination-indicated cerclage, those who started progestogen therapy before cerclage, and in sites restricted to the United States. CONCLUSION: Use of progestogen with cerclage was associated with reduced rates of spontaneous preterm birth and early spontaneous preterm birth compared with cerclage alone. Although this study was not sufficiently powered for subgroup analysis, the strength of evidence for benefit appeared greatest for those with ultrasound- or examination-indicated cerclage, and with vaginal progesterone. El resumen está disponible en Español al final del artículo.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Tolosa JE, Boelig RC, Bell J, et al. Concurrent progestogen and cerclage to reduce preterm birth: a multicenter international retrospective cohort. Am J Obstet Gynecol MFM. 2024. PMID: 38513806. doi:10.1016/j.ajogmf.2024.101351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。